As the great imitator, IgG4-RD can closely mimic any number of diseases throughout the body, necessitating a multidisciplinary approach to diagnosing and managing the disease. However, unlike many of its mimics, IgG4-RD can be effectively treated, if diagnosed early. Led by Dr. John Stone (Program Chair, rheumatologist), this case-based panel discussion offers a unique, interactive experience to deepen your understanding of IgG4-RD. Together with a distinguished multidisciplinary faculty team – Drs. Avinash Kambadakone (radiologist), Matthias Löhr (gastroenterologist), and Yoh Zen (pathologist) – the session will delve into complex cases, presenting them in a step-by-step manner. Through collaborative analysis and discussions, this panel promises to provide valuable insights into the nuances of diagnosing and managing IgG4-RD.
ReachMD
Be part of the knowledge.™We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
Dive into the complexities of IgG4-related disease (IgG4-RD) with this interactive case conference. Participate in live polls as a multidisciplinary panel discuss interesting cases and test your diagnostic acumen in real-time!
This live broadcast will start in exactly:
- 0
Day(s)
- 0
Hour(s)
- 0
Minute(s)
- 0
Second(s)
Overview
Disclosure of Conflicts of Interest
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.The following faculty/staff members have the following financial relationships with ineligible companies.
John H. Stone, MD, MPH, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Acepodia, Alexion, Alpine Immune Sciences, Amgen, Argenx, Connect Biopharma, CTI BioPharma, Genentech, Horizon Therapeutics, iCell Gene Therapeutics, IQVIA, Merck, Norartis, Polaris, Q32 Bio, Salvina Therapeutics, Sanofi, and ZenasBio. Grant/Research Support: Bristol-Myers Squib, Horizon Therapeutics, and Sanofi.
Avinash Kambadakone-Ramesh, MD, DNB, FRCR, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Bayer. Grant/Research Support: Bayer, GE HealthCare, and PanCAN.
J. Matthias Löhr, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Falk Pharma and Zedira. Shareholder: Centogene, iCellate, and Pharmacyte.
Yoh Zen, MD, PhD, FRCPath, has had no financial relationships or affiliations with ineligible companies.
The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Describe the prevalence, etiology, and pathophysiology of IgG4-related disease
- Identify the individual organ manifestations/clinical features that may support a diagnosis of IgG4-related disease
- Outline the diseases and/or conditions whose manifestations have substantial overlap with IgG4-RD
- Analyze clinical, serological, histopathological, and radiological findings to facilitate early diagnosis of patients with IgG4-related disease
- Explain how patients with IgG4-RD are currently treated
- Develop effective co-management strategies to improve outcomes for patients with IgG4-RD
Target Audience
This certified continuing education activity is designed for rheumatologists, nurse practitioners, and physician assistants, as well as pathologists and radiologists who diagnose and treat patients involved in the diagnosis and management of IgG4-related disease.
Accreditation and Credit Designation Statements
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu.
Provider(s)/Educational Partner(s)
Evolve Medical Education LLC (Evolve) is a leader in cultivating health care for patients by educating clinical competence of the health care team. Evolve achieves this by developing and distributing high-quality, evidence-based, valid, independent CME/CE activities in a variety of learning formats. These activities are designed to increase clinician’s knowledge, skills, competence and professional performance as well as to promote professional growth, maintenance of licensure, and support quality change in care of patients.
Commercial Support
This activity is supported by an independent medical education grant from Amgen.
Disclaimer
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Amgen.This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Overview
As the great imitator, IgG4-RD can closely mimic any number of diseases throughout the body, necessitating a multidisciplinary approach to diagnosing and managing the disease. However, unlike many of its mimics, IgG4-RD can be effectively treated, if diagnosed early. Led by Dr. John Stone (Program Chair, rheumatologist), this case-based panel discussion offers a unique, interactive experience to deepen your understanding of IgG4-RD. Together with a distinguished multidisciplinary faculty team – Drs. Avinash Kambadakone (radiologist), Matthias Löhr (gastroenterologist), and Yoh Zen (pathologist) – the session will delve into complex cases, presenting them in a step-by-step manner. Through collaborative analysis and discussions, this panel promises to provide valuable insights into the nuances of diagnosing and managing IgG4-RD.
Disclosure of Conflicts of Interest
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.The following faculty/staff members have the following financial relationships with ineligible companies.
John H. Stone, MD, MPH, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Acepodia, Alexion, Alpine Immune Sciences, Amgen, Argenx, Connect Biopharma, CTI BioPharma, Genentech, Horizon Therapeutics, iCell Gene Therapeutics, IQVIA, Merck, Norartis, Polaris, Q32 Bio, Salvina Therapeutics, Sanofi, and ZenasBio. Grant/Research Support: Bristol-Myers Squib, Horizon Therapeutics, and Sanofi.
Avinash Kambadakone-Ramesh, MD, DNB, FRCR, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Bayer. Grant/Research Support: Bayer, GE HealthCare, and PanCAN.
J. Matthias Löhr, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Falk Pharma and Zedira. Shareholder: Centogene, iCellate, and Pharmacyte.
Yoh Zen, MD, PhD, FRCPath, has had no financial relationships or affiliations with ineligible companies.
The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Describe the prevalence, etiology, and pathophysiology of IgG4-related disease
- Identify the individual organ manifestations/clinical features that may support a diagnosis of IgG4-related disease
- Outline the diseases and/or conditions whose manifestations have substantial overlap with IgG4-RD
- Analyze clinical, serological, histopathological, and radiological findings to facilitate early diagnosis of patients with IgG4-related disease
- Explain how patients with IgG4-RD are currently treated
- Develop effective co-management strategies to improve outcomes for patients with IgG4-RD
Target Audience
This certified continuing education activity is designed for rheumatologists, nurse practitioners, and physician assistants, as well as pathologists and radiologists who diagnose and treat patients involved in the diagnosis and management of IgG4-related disease.
Accreditation and Credit Designation Statements
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu.
Provider(s)/Educational Partner(s)
Evolve Medical Education LLC (Evolve) is a leader in cultivating health care for patients by educating clinical competence of the health care team. Evolve achieves this by developing and distributing high-quality, evidence-based, valid, independent CME/CE activities in a variety of learning formats. These activities are designed to increase clinician’s knowledge, skills, competence and professional performance as well as to promote professional growth, maintenance of licensure, and support quality change in care of patients.
Commercial Support
This activity is supported by an independent medical education grant from Amgen.
Disclaimer
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Amgen.This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Facebook Comments